Shots:

• The first patient has been dosed in a P-l/ll study assessing the safety of APL-1202 + BeiGene's tislelizumab as a neoadjuvant therapy in patients with muscle invasive bladder cancer (MIBC)
• The focus of the study is to determine the recommended Phase 2 dose (RP2D) and to evaluate the efficacy as neoadjuvant therapy for MIBC
• APL-1202 is an orally available reversible MetAP2 Inhibitor whereas Tislelizumab is a humanized IgG4 anti-PD-1 mAb, designed to minimize binding to FcγR on macrophages. The combination regimen has the potential to be the best treatment option for MIBC patients

Ref: PR Newswire | Image: Cancer Therapy Advisor